Close Menu

New York-Presbyterian Hospital

After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

The test, EXaCT-1, may not only help doctors find treatments for patients who have run out of options but may also provide biomarkers of immunotherapy response.

The Irving Institute, a CUMC partnership with New York-Presbyterian, will fund its precision medicine program and the development of new therapies.

NEW YORK (GenomeWeb News) – Weill Cornell Medical College and New York-Presbyterian Hospital have partnered to launch a new institute that will pursue genome-centered translational medicine to deliver personalized care.

In the May issue of Cancer Prevention Research, Steven Lipkin and colleagues reported that in colon cancer cell lines, the protective effect against colorectal cancer was stronger in cells with a particular SNP in the HMGCR gene.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.